RenovoRx, Inc. (RNXT)
1.28
-0.05
(-3.76%)
USD |
NASDAQ |
Oct 09, 16:00
1.32
+0.04
(+3.12%)
Pre-Market: 20:00
RenovoRx Cash from Investing (Quarterly) : -0.071M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.071M |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | -0.002M |
| December 31, 2024 | -0.012M |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2023 | 2.032M |
| December 31, 2022 | 2.976M |
| September 30, 2022 | 2.992M |
| June 30, 2022 | -8.00M |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | -0.015M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | 14.00M |
| Travere Therapeutics, Inc. | -206.29M |
| REGENXBIO, Inc. | 65.92M |
| Krystal Biotech, Inc. | -161.58M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.867M |
| Cash from Financing (Quarterly) | 0.055M |
| Free Cash Flow | -11.94M |
| Free Cash Flow Per Share (Quarterly) | -0.0621 |
| Free Cash Flow to Equity (Quarterly) | -3.142M |
| Free Cash Flow to Firm (Quarterly) | -2.938M |
| Free Cash Flow Yield | -23.52% |